Abstract
Background Gallbladder cancer is a grave threat to human health and poses a severe economic burden. Enhanced CT is extensively used in the diagnosis of gallbladder tumors. However, false-positive results of enhanced CT can lead to misdiagnosis. As a result, patients have to bear unnecessary mental pain, expensive surgery and examination costs, surgical trauma, organ removal, loss of function, and even serious perioperative complications. False-negative enhanced CT results can lead to delayed treatment. Patients will thus have to bear the adverse consequences of negative prognosis, high treatment costs, poor quality of life, and short survival. There is an urgency to find convenient, cost-effective and noninvasive diagnostic methods to decrease the false-negative and false-positive rates of gallbladder-enhanced CT. The goal of this study was to assess the diagnostic value of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D in gallbladder cancer.
Patients and methods Fifty study subjects (malignant group, n=12; benign group, n=38 cases) were finally recruited in the study. Remaining serum samples from the subjects were collected and tested by applying YiDiXie ™ all-cancer detection kit (YiDiXie™ all-cancer detection kit) to assess the sensitivity and specificity of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D, respectively.
Results YiDiXie™-SS had a sensitivity of 100% (95% CI: 75.8% - 100%) and a specificity of 65.8% (95% CI: 49.9% - 78.8%). YiDiXie™-HS had a sensitivity of 91.7% (95% CI: 64.6% - 99.6%) and a specificity of 84.2% (95% CI: 69.6% - 92.6%). YiDiXie™-D had a sensitivity of 41.7% (95% CI: 19.3% - 68.0%) and a specificity of 97.4% (95% CI: 86.5% - 99.9%). YiDiXie™-SS had a sensitivity of 100% (95% CI: 64.6% - 100%) and its specificity was 60.0% (95% CI: 31.3% - 83.2%) in patients with positive enhanced CT. This implies that the application of YiDiXie™-SS decreases the false-positive rate of enhanced CT of the gallbladder by 60.0% (95% CI: 31.3% - 83.2%) with essentially no increase in the leakage of gallbladder cancer. YiDiXie™-HS has a sensitivity of 80.0% (95% CI: 37.6% - 99.0%) in patients with a negative enhanced CT, and its specificity was 85.7% (95% CI: 68.5% - 94.3%). This implies that the application of YiDiXie™-HS reduces the false-negative rate of enhanced CT by 80.0% (95% CI: 37.6% - 99.0%). YiDiXie ™ -D has a sensitivity of 28.6% (95% CI: 5.1% - 64.1%) in patients with a positive enhanced CT and a specificity of 100% (95% CI: 72.2% - 100%). This implies that YiDiXie™-SS decreases the false positive rate of enhanced CT by 100% (95% CI: 72.2% - 100%).
Conclusion YiDiXie ™ -SS markedly decreased the rate of false-positive gallbladder-enhanced CT with basically no increase in deferred treatment of gallbladder cancer. YiDiXie ™ -HS significantly decreases the false-negative rate of gallbladder-enhanced CT. YiDiXie™-D significantly decreases the false-positive rate of gallbladder-enhanced CT. The YiDiXie™ test has an excellent diagnostic value in gallbladder cancer, and expected to address the problems of “high false-positive rate of enhanced CT” and “high false-negative rate of enhanced CT” in gallbladder tumors.
Clinical trial number ChiCTR2200066840.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR2200066840
Funding Statement
This work was supported by Shenzhen High-level Hospital Construction Fund, Clinical Research Project of Peking University Shenzhen Hospital (LCYJ2020002, LCYJ2020015, LCYJ2020020, LCYJ2017001).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Peking University Shenzhen Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are contained in the manuscript.
